A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vac (Q56288717)

From Wikidata

Jump to navigation Jump to search

scientific article published in 2012

Language	Label	Description	Also known as
English	A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vac	scientific article published in 2012

Statements

scholarly article

0 references

A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vac (English)

0 references

1 reference

based on heuristic

inferred from title

object named as

Tine Dalby

4

0 references

author name string

Birgit Thierry-Carstensen

1

0 references

Karina Jordan

2

0 references

Hilde Hylland Uhlving

3

0 references

Charlotte Sørensen

5

0 references

Anders Mørup Jensen

6

0 references

Carsten Heilmann

7

0 references

language of work or name

0 references

publication date

August 2012

0 references

0 references

30

0 references

37

0 references

5464-5471

0 references

Rationale for pertussis booster vaccination throughout life in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Duration of immunity against pertussis after natural infection or vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Comparison of pertussis surveillance systems in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Development and clinical testing of multivalent vaccines based on a diphtheria–tetanus–acellular pertussis vaccine: difficulties encountered and lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Acellular pertussis vaccines and the role of pertactin and fimbriae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Pertussis vaccine: a critique

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Improved ELISA for determination of anti-diphtheria and/or anti-tetanus antitoxin antibodies in sera.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Problem solved: a modified enzyme-linked immunosorbent assay for detection of human antibodies to pertussis toxin eliminates false-positive results occurring at analysis of heat-treated sera.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

DTaP vaccines from north american vaccine (NAVA): composition and critical parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Seroprevalence of pertussis among Danish patients with cough of unknown etiology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immunity to pertussis 5 years after booster immunization during adolescence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.073

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.06.073

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56288717&oldid=2221369087"